SLU-PP-332

SLU-PP-332

Saint Louis University Pan-ERR Agonist 332

Exercise-mimetic ERR agonist for endurance and fat loss

Fat LossMuscle GrowthLongevity ★ 55
Half-life
Not formally established in humans; measurable plasma and muscle levels at 6 hours in mice (supports BID preclinical dosing)
Cycle
6-8 week cycles aligned with published chronic mouse studies; 4-week breaks recommended between cycles.
Storage
Lyophilized: months refrigerated, longer at -20°C. Reconstituted: 2-8°C light-protected, 2-4 weeks. Oral tablets: room temperature, dry, dark.
Research
Preclinical only — no human pharmacokinetic or safety data

About

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ), nuclear receptors that drive mitochondrial biogenesis and oxidative metabolism. By directly activating the same transcriptional program triggered by endurance exercise, it raises oxidative muscle fiber content and energy expenditure without mechanical loading. It is approximately 4-fold more potent at ERRα than ERRγ, favoring muscle and metabolic tissue effects. Despite striking rodent efficacy, no human trials exist as of 2026.

Mechanism

Pan-agonism of ERRα/β/γ nuclear receptors increases mitochondrial biogenesis, fatty-acid oxidation, and type IIa oxidative muscle-fiber formation — reproducing the transcriptional signature of aerobic exercise.

Dosage

12.5-25 mg
1x per day
0102030405060708090100

Draw to 1000 units on a U-100 insulin syringe

5 mg · 2 mL BAC

Route
Oral
Duration
4 weeks

When to take: Morning dosing preferred to avoid sleep disruption from stimulatory effects. BID protocols split morning and early afternoon.

Reconstitution

Vial size (mg): 5 mg · BAC water (mL): 2 mL · Concentration: 2500 mcg/mL

Inject BAC water slowly down vial wall; swirl gently. Protect reconstituted solution from light — deepening yellow color indicates oxidation, replace if observed.

Benefits

  • 25-30% fat-mass reduction in diet-induced obese mice (28 days)
  • Increased treadmill endurance and oxidative muscle fiber content
  • Improved glucose tolerance without altered food intake
  • Improved cardiac ejection fraction in heart-failure mouse models
  • Restored mitochondrial function in aging kidney models

Side effects

  • Sleep disruption and stimulatory effects
  • Increased resting heart rate
  • Appetite changes (community reports)
  • Unknown chronic cardiovascular risk
  • Uncertain cancer-metabolism interactions (ERRα implicated in some tumor pathways)

Gender notes

Standard dosing applies. Popular in endurance and body-recomposition stacks.

Cautions

  • Pregnancy and breastfeeding
  • Age under 18
  • Active or recent cancer history
  • Cardiovascular disease, arrhythmia, uncontrolled hypertension
  • Significant liver or kidney impairment
  • WADA-tested competitive athletes (falls under S4.5 metabolic modulators)
  • Concurrent stimulants without clinical oversight

Research

Stacks well with

MOTS-c5-Amino-1MQAOD-9604Tesamorelin
Add reminder Calculator